Aleglitazar
From Self-sufficiency
Revision as of 20:12, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s): gastrointestinal-drug-stub)
| Aleglitazar | |
|---|---|
| File:Aleglitazar.svg | |
| (2S)-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-
7-benzothiophenyl]propanoic acid | |
| Other names Ro-0728804, R-1439 | |
| style="background: #F8EABA; text-align: center;" colspan="2" | Identifiers | |
| CAS number | 475479-34-6 |
| PubChem | 10274777 |
| SMILES | Script error: No such module "collapsible list". |
| style="background: #F8EABA; text-align: center;" colspan="2" | Properties | |
| Molecular formula | C24H23NO5S |
| Molar mass | 437.50812 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Aleglitazar is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, which is being developed by Hoffmann–La Roche for the treatment of type II diabetes.[1] It is currently in phase II clinical trials.[2]
References
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 45px | This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. |
- ↑ "Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar" (PDF). United States Adopted Names. American Medical Association. Retrieved 2008-08-17.
- ↑ ClinicalTrials.gov. "A Study of Aleglitazar in Patients With Type 2 Diabetes". United States National Institutes of Health. Retrieved 2008-03-19.
